Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | TCF4 | P15884 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1428091 | 0.88 | ERN1 (0.62) | ERN1ALDH1A1TDP1LMNACYP1A1 | |
| SCHEMBL1459113 | 0.86 | ERN1 (0.43) | ERN1ALDH1A1CYP2A6LMNACYP1A1 | |
| SCHEMBL5623138 | 0.86 | ERN1 (0.71) | ERN1ALDH1A1LMNATRIM24TYR | |
| SCHEMBL8679138 | 0.80 | MAPT (0.45) | ERN1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL24132612 | 0.78 | ALDH1A1 (0.38) | ERN1ALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL1250536 | 0.78 | NPC1 (0.57) | ALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL7044261 | 0.77 | LMNA (0.42) | ERN1ALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL1040963 | 0.77 | ALDH1A3 (0.47) | ERN1ALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL14352949 | 0.77 | TDP1 (0.37) | ALDH1A1TDP1MEN1KMT2A | |
| 2,4,6-Trimethoxybenzaldehyde SCHEMBL34873 | 0.74 | ERN1 (0.74) | ERN1ALDH1A1TDP1LMNACYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590080-B2 | Compounds | PAKINAX PTY LTD. (AU) | 2026-03-31 | — | — | US | disclosed |
| US-12006294-B2 | Therapeutic compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | disclosed |
| US-20230242519-A1 | NOVEL COMPOUNDS | PAKINAX PTY LTD. (AU) | 2023-08-03 | — | — | US | disclosed |
| US-20230242519-A1 | NOVEL COMPOUNDS | PAKINAX PTY LTD. (AU) | 2023-08-03 | — | — | US | disclosed |
| US-20230242519-A1 | NOVEL COMPOUNDS | PAKINAX PTY LTD. (AU) | 2023-08-03 | — | — | US | disclosed |
| EP-4204400-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | Fibrogen, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116348450-A | Compounds, compositions and methods for histone lysine demethylase inhibition | 菲布罗根有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| CN-112920158-B | Spirobifluorene compound, material containing the compound, and organic electroluminescent device and electronic device comprising the material | 北京八亿时空液晶科技股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| EP-0542371-A1 | Saccharin derivative proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1993-05-19 | — | — | EP | disclosed |
| EP-0193055-B1 | ANTITUMORALS(1,2-DIPHENYL-ETHYLENE DIAMINE)-PLATINUM (II) COMPLEXES | ASTA Pharma AG (DE) | 1990-05-16 | — | — | EP | disclosed |
| US-4730068-A | SPECIAL EFFECT ON BREAST CANCER | ASTA-WERKE AKTIENGESELLSCHAFT (DE) | 1988-03-08 | — | — | US | disclosed |
| US-4661511-A | ANTITUMOR AGENTS | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1987-04-28 | — | — | US | disclosed |
| EP-0193055-A1 | Antitumorals(1,2-diphenyl-ethylene diamine)-platinum (II) complexes | ASTA Pharma AG (DE) | 1986-09-03 | — | — | EP | disclosed |
| US-4543360-A | ANTIESTROGENS, ANTITUMOR | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1985-09-24 | — | — | US | disclosed |
| US-4235999-A | Bichromophoric benzotriazole-styrene ester ultraviolet stabilizers and their use in organic compositions | EASTMAN KODAK COMPANY (US) | 1980-11-25 | — | — | US | disclosed |
| US-4129723-A | Bichromophoric benzoxazole-styrene ester and amide ultraviolet stabilizers and their use in organic compositions | EASTMAN KODAK COMPANY (US) | 1978-12-12 | — | — | US | disclosed |
| US-4070339-A | Bichromophoric benzotriazole-styrene ester ultraviolet stabilizers and their use in organic compositions | EASTMAN KODAK COMPANY (US) | 1978-01-24 | — | — | US | disclosed |
| US-4062800-A | Bichromophoric benzoxazole-styrene ester and amide ultraviolet stabilizers and their use in organic compositions | EASTMAN KODAK COMPANY (US) | 1977-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | ERN1 3226/4885ALDH1A1 2057/4885TDP1 4787/4885 |
| US-12590080-B2 | Compounds | PAK4, PAK2, PAK1 | ERN1 1272/4885ALDH1A1 2984/4885TDP1 2026/4885 |
| US-20230242519-A1 | NOVEL COMPOUNDS | PAK4, PAK2, PAK1 | ERN1 2036/4885ALDH1A1 3084/4885TDP1 1196/4885 |
| US-12006294-B2 | Therapeutic compounds | OPRL1, INA, OGFR | ERN1 2522/4885ALDH1A1 1048/4885TDP1 3890/4885 |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | KDM5C, KDM5B, KDM5A | ERN1 1481/4885ALDH1A1 2449/4885TDP1 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.